



News
Stanford Medicine-led research identifies a subtype of depression

Written by
Written by
Matt Kuntz
Matt Kuntz
Posted on
Posted on
Jun 27, 2023
Jun 27, 2023
Category
Category
Mental Health Awareness
Mental Health Awareness



by Emily Moskal for Stanford Medicine News
Using surveys, cognitive tests and brain imaging, researchers have identified a type of depression that affects about a quarter of patients. The goal is to diagnose and treat the condition more precisely.
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
Cognitive tasks showed that these patients have difficulty with the ability to plan ahead, display self-control, sustain focus despite distractions and suppress inappropriate behavior; imaging showed decreased activity in two brain regions responsible for those tasks.
Because depression has traditionally been defined as a mood disorder, doctors commonly prescribe antidepressants that target serotonin (known as selective serotonin reuptake inhibitors or SSRIs), but these are less effective for patients with cognitive dysfunction. Researchers said that targeting these cognitive dysfunctions with less commonly used antidepressants or other treatments may alleviate symptoms and help restore social and occupational abilities.
The study, published June 15 in JAMA Network Open, is part of a broader effort by neuroscientists to find treatments that target depression biotypes, according to the study’s senior author, Leanne Williams, PhD, the Vincent V.C. Woo Professor and professor of psychiatry and behavioral sciences.
“One of the big challenges is to find a new way to address what is currently a trial-and-error process so that more people can get better sooner,” Williams said. “Bringing in these objective cognitive measures like imaging will make sure we’re not using the same treatment on every patient.”
Read the full artiticle at this link.
by Emily Moskal for Stanford Medicine News
Using surveys, cognitive tests and brain imaging, researchers have identified a type of depression that affects about a quarter of patients. The goal is to diagnose and treat the condition more precisely.
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
Cognitive tasks showed that these patients have difficulty with the ability to plan ahead, display self-control, sustain focus despite distractions and suppress inappropriate behavior; imaging showed decreased activity in two brain regions responsible for those tasks.
Because depression has traditionally been defined as a mood disorder, doctors commonly prescribe antidepressants that target serotonin (known as selective serotonin reuptake inhibitors or SSRIs), but these are less effective for patients with cognitive dysfunction. Researchers said that targeting these cognitive dysfunctions with less commonly used antidepressants or other treatments may alleviate symptoms and help restore social and occupational abilities.
The study, published June 15 in JAMA Network Open, is part of a broader effort by neuroscientists to find treatments that target depression biotypes, according to the study’s senior author, Leanne Williams, PhD, the Vincent V.C. Woo Professor and professor of psychiatry and behavioral sciences.
“One of the big challenges is to find a new way to address what is currently a trial-and-error process so that more people can get better sooner,” Williams said. “Bringing in these objective cognitive measures like imaging will make sure we’re not using the same treatment on every patient.”
Read the full artiticle at this link.
by Emily Moskal for Stanford Medicine News
Using surveys, cognitive tests and brain imaging, researchers have identified a type of depression that affects about a quarter of patients. The goal is to diagnose and treat the condition more precisely.
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
Cognitive tasks showed that these patients have difficulty with the ability to plan ahead, display self-control, sustain focus despite distractions and suppress inappropriate behavior; imaging showed decreased activity in two brain regions responsible for those tasks.
Because depression has traditionally been defined as a mood disorder, doctors commonly prescribe antidepressants that target serotonin (known as selective serotonin reuptake inhibitors or SSRIs), but these are less effective for patients with cognitive dysfunction. Researchers said that targeting these cognitive dysfunctions with less commonly used antidepressants or other treatments may alleviate symptoms and help restore social and occupational abilities.
The study, published June 15 in JAMA Network Open, is part of a broader effort by neuroscientists to find treatments that target depression biotypes, according to the study’s senior author, Leanne Williams, PhD, the Vincent V.C. Woo Professor and professor of psychiatry and behavioral sciences.
“One of the big challenges is to find a new way to address what is currently a trial-and-error process so that more people can get better sooner,” Williams said. “Bringing in these objective cognitive measures like imaging will make sure we’re not using the same treatment on every patient.”
Read the full artiticle at this link.
by Emily Moskal for Stanford Medicine News
Using surveys, cognitive tests and brain imaging, researchers have identified a type of depression that affects about a quarter of patients. The goal is to diagnose and treat the condition more precisely.
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
Cognitive tasks showed that these patients have difficulty with the ability to plan ahead, display self-control, sustain focus despite distractions and suppress inappropriate behavior; imaging showed decreased activity in two brain regions responsible for those tasks.
Because depression has traditionally been defined as a mood disorder, doctors commonly prescribe antidepressants that target serotonin (known as selective serotonin reuptake inhibitors or SSRIs), but these are less effective for patients with cognitive dysfunction. Researchers said that targeting these cognitive dysfunctions with less commonly used antidepressants or other treatments may alleviate symptoms and help restore social and occupational abilities.
The study, published June 15 in JAMA Network Open, is part of a broader effort by neuroscientists to find treatments that target depression biotypes, according to the study’s senior author, Leanne Williams, PhD, the Vincent V.C. Woo Professor and professor of psychiatry and behavioral sciences.
“One of the big challenges is to find a new way to address what is currently a trial-and-error process so that more people can get better sooner,” Williams said. “Bringing in these objective cognitive measures like imaging will make sure we’re not using the same treatment on every patient.”
Read the full artiticle at this link.
Recommended News

Mental Health Policy
Jun 14, 2023
News Flash: Gianforte signs state budget, boosting Medicaid reimbursements by hundreds of millions
Governor Greg Gianforte signs budget increasing Montana Medicaid provider rates. A great step forward for Montana's mental health care system.

Mental Health Information
Mar 3, 2023
Understanding Major Depression: Symptoms and Causes
Depression is a common mental health disorder that affects millions of people around the world.

Mental Health Information
Mar 7, 2023
The Benefits of Cognitive Behavioral Therapy for Anxiety
Anxiety disorders are among the most common mental health disorders worldwide. According to the World Health Organization, one in 13 people globally suffers from anxiety disorders.

Mental Health Policy
Jun 14, 2023
News Flash: Gianforte signs state budget, boosting Medicaid reimbursements by hundreds of millions
Governor Greg Gianforte signs budget increasing Montana Medicaid provider rates. A great step forward for Montana's mental health care system.

Mental Health Information
Mar 3, 2023
Understanding Major Depression: Symptoms and Causes
Depression is a common mental health disorder that affects millions of people around the world.

Mental Health Policy
Jun 14, 2023
News Flash: Gianforte signs state budget, boosting Medicaid reimbursements by hundreds of millions
Governor Greg Gianforte signs budget increasing Montana Medicaid provider rates. A great step forward for Montana's mental health care system.

Mental Health Information
Mar 3, 2023
Understanding Major Depression: Symptoms and Causes
Depression is a common mental health disorder that affects millions of people around the world.

Help Us With This Important Mission
We rely on donor support for all of our work. We can't do this without you!

Help Us With This Important Mission
We rely on donor support for all of our work. We can't do this without you!

Help Us With This Important Mission
We rely on donor support for all of our work. We can't do this without you!

Help Us With This Important Mission
We rely on donor support for all of our work. We can't do this without you!

Stay Connected to Better Health
We are mental health experienced therapists that are passionate about our goal on empowering you mentally with our wellness journey.
© 2025 NAMI Montana
Privacy Policy
Terms & Conditions

Stay Connected to Better Health
We are mental health experienced therapists that are passionate about our goal on empowering you mentally with our wellness journey.
© 2025 NAMI Montana
Privacy Policy
Terms & Conditions

Stay Connected to Better Health
We are mental health experienced therapists that are passionate about our goal on empowering you mentally with our wellness journey.
© 2025 NAMI Montana
Privacy Policy
Terms & Conditions